Treatment with each inhibitor in breast and gastric cancer cells had negligible effects on TAZ expression, suggesting that the FLT3-JAK-STAT3-TAZ-TEAD signaling is unique to FLT3+ CML cells (Fig. 3J, S3C). This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.